T3 Beta-AT Injection

T3 Beta-AT Injection contains Artesunate, which is a medication primarily utilized for the treatment of malaria, particularly in severe cases. Belonging to the artemisinin class of medications holds a place on the World Health Organization's List of Essential Medicines.

It functions as a prodrug, rapidly converting to its active form, dihydroartemisinin (DHA). This transformation generates reactive oxygen species, inducing oxidative stress and causing damage to malarial proteins. Additionally, it inhibits the essential Plasmodium falciparum exported protein 1 (EXP1), reducing parasite glutathione levels.

While generally well tolerated, common side effects may include a slow heartbeat, allergic reactions, dizziness, and low white blood cell levels. In severe cases, kidney failure requiring dialysis, hemoglobinuria (presence of hemoglobin in urine), and jaundice have been reported.

It is considered safe during pregnancy, particularly in the second and third trimesters, although caution is advised in the first trimester. It is generally safe for use in children, with adjustments in dosing for those under 20 kg. Notably, it should be avoided in newborns when combined with sulfadoxine/pyrimethamine due to potential effects on bilirubin.

In the event of a missed dose, it is crucial to consult with a healthcare professional for guidance on the appropriate course of action. The timing and severity of the missed dose will be considered to determine the most suitable response.